SMi Reports: The morning session on day two of SMi’s RNA Therapeutics conference will pay a particular focus to “Downregulating Therapeutic Technologies”.
LONDON, UNITED KINGDOM, November 11, 2019 /EINPresswire.com/ — SMi are proud to host the 11th annual RNA Therapeutics conference on February 19th – 20th 2020 in London. This year’s event will maintain a focus on the latest research and developments on delivery system technologies aimed at tackling difficult targets within the human body.
An early bird savings of £200 expires on 29th November. Interested parties are encouraged to register early at www.therapeutics-rna.com/einpr4
The conference will pay close attention to regulations within the field of RNA Therapeutics, such as, continuing upon patenting novel products, the release of new 2020 regulations in the clinical trials arena and ensuring compliance. The agenda for the morning of day two will highlight “Downregulating Therapeutic Technologies”.
Session Highlights Include:
MiRNA Therapeutics: From Discovery to the Bedside
• The non-coding genome makes up 98.8% of the human genome. Most of this non-coding genome is transcribed into non-coding RNAs that may play an important role in cellular regulation in health and disease; these non-coding RNAs could be novel targets for future medicines.
• MicroRNAs are short non-coding RNAs that regulate biochemical pathways and networks of pathways by the mechanism of RNA interference (RNAi). MicroRNA-21 has been implicated in multiple organs as a microRNA associated with fibrotic diseases and cancer.
• The presentation will summarise the opportunities and challenges of developing microRNA-based drugs and will illustrate the successful generation of an anti-fibrotic microRNAbased therapeutic approach by targeting microRNA-21 with an antisense oligonucleotide (anti-miR-21). This microRNA-based drug is now in a phase 2 clinical trial for a fibrotic kidney disease called Alport Syndrome.
Ekkehard Leberer, Senior Director, Alliance Management, Sanofi
MicroRNA Replacement Therapy: Myth or Reality?
• miRNAs – Mother Nature has already done most of the job! …
• miRNAs as novel therapeutic intervention in Oncology
• miRNA replacement therapy (miRNA mimics)
Michel Janicot, Chief Development Officer, InteRNA Technologies
NanoGenics; Using a peptide nanoparticle, LipTide, to develop a siRNA product portfolio
• How does the peptide nanoparticle, LipTide resemble an artificial virus?
• Delivering siRNA with LipTide across multiple administration routes
• Case study; Targeting the MRTF pathway to develop siRNA anti-fibrotic drugs
Simon Newman, CSO, Nanogenics
This year’s agenda also includes a Focus Day held the 18th of February including sessions on recent developments in “Oligonucleotide Delivery Systems”.
View the full event programme at www.therapeutics-rna.com/einpr4
Focus Day: 18th February 2020
Conference: 19th – 20th February 2020
Copthorne Tara Hotel, London, UK
Proudly sponsored by:
ChemGenes | Thermo Fisher Scientific
— ENDS –
For media enquiries contact Alia Malick on +44 (0)20 7827 6168
For all delegate enquiries, contact Hakam Panum on +44 (0)20 7827 6128
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
SMi Group Ltd
+44 20 7827 6000
email us here
Source: EIN Presswire